Payment overview · 2025
General Payments
$340.02
5 reported records · 4 companies
Healthcare provider profile · identity verified
Yolanda Alvarez Pando, MD
Allopathic & Osteopathic Physicians|General Practice · LAKELAND, FL · NPI 1912520834
Verified facts
What the public records show
CMS Open Payments records show Yolanda Alvarez Pando, MD received $340.02 in general payments during 2025 across 5 reported records.
AstraZeneca Pharmaceuticals LP accounted for 52.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $180.00 | 52.9% | 2 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $119.36 | 35.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.18 | 6.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.48 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $340.02 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $119.36 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $55.00 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
102 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 716 | 248 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 504 | 136 |
| Lisinopril | Lisinopril | 474 | 162 |
| Gabapentin | Gabapentin | 420 | 108 |
| Metformin Hcl | Metformin Hcl | 410 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 408 | 138 |
| Omeprazole | Omeprazole | 375 | 133 |
| Losartan Potassium | Losartan Potassium | 354 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 330 | 98 |
| Diclofenac Sodium | Diclofenac Sodium | 293 | 117 |
| Simvastatin | Simvastatin | 271 | 95 |
| Hydrochlorothiazide | Hydrochlorothiazide | 249 | 91 |
| Glipizide | Glipizide | 242 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 216 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 190 | 74 |
| Fluticasone Propionate | Fluticasone Propionate | 186 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 185 | 66 |
| Alendronate Sodium | Alendronate Sodium | 173 | 57 |
| Carvedilol | Carvedilol | 166 | 52 |
| Furosemide | Furosemide | 142 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 46 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 134 | 54 |
| Montelukast Sodium | Montelukast Sodium | 133 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 42 |
| Trazodone Hcl | Trazodone Hcl | 119 | 47 |
| Famotidine | Famotidine | 116 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 51 |
| Eliquis | Apixaban | 102 | 29 |
| Fenofibrate | Fenofibrate | 102 | 50 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 97 | 89 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 97 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 30 |
| Ibuprofen | Ibuprofen | 78 | 41 |
| Prednisone | Prednisone | 76 | 48 |
| Ezetimibe | Ezetimibe | 75 | 28 |
| Breyna | Budesonide/Formoterol Fumarate | 72 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 38 |
| Glimepiride | Glimepiride | 71 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 26 |
| Sertraline Hcl | Sertraline Hcl | 67 | 25 |
| Sucralfate | Sucralfate | 67 | 19 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 66 | 15 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 66 | 13 |
| Buspirone Hcl | Buspirone Hcl | 64 | 20 |
| Meclizine Hcl | Meclizine Hcl | 61 | 34 |
| Jardiance | Empagliflozin | 60 | 18 |
| Ketoconazole | Ketoconazole | 60 | 29 |
| Memantine Hcl | Memantine Hcl | 59 | 21 |
| Allopurinol | Allopurinol | 55 | 19 |
| Januvia | Sitagliptin Phosphate | 55 | 19 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 53 | 45 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 33 |
| Symbicort | Budesonide/Formoterol Fumarate | 47 | 15 |
| Azithromycin | Azithromycin | 46 | 36 |
| Ciclopirox | Ciclopirox Olamine | 45 | 24 |
| Nitroglycerin | Nitroglycerin | 45 | 24 |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 16 |
| Valsartan | Valsartan | 43 | 14 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 41 | 15 |
| Timolol Maleate | Timolol Maleate | 41 | suppressed |
| Atenolol | Atenolol | 40 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 12 |
| Enalapril Maleate | Enalapril Maleate | 39 | 11 |
| Alprazolam | Alprazolam | 37 | 11 |
| Cephalexin | Cephalexin | 37 | 33 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 21 |
| Baclofen | Baclofen | 35 | 14 |
| Latanoprost | Latanoprost | 34 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 11 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 27 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 11 |
| Mupirocin | Mupirocin | 30 | 25 |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 27 | suppressed |
| Bumetanide | Bumetanide | 26 | 15 |
| Hydrocortisone | Hydrocortisone | 26 | 20 |
| Meloxicam | Meloxicam | 26 | 16 |
| Spironolactone | Spironolactone | 26 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Nifedipine Er | Nifedipine | 23 | 13 |
| Folic Acid | Folic Acid | 22 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Pentoxifylline | Pentoxifylline | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 17 | suppressed |
| Levemir | Insulin Detemir | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 15 |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 14 |
| Calcitriol | Calcitriol | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Naproxen | Naproxen | 14 | 13 |
| Ramelteon | Ramelteon | 14 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | 11 |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 12 | suppressed |
| Xcopri | Cenobamate | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $340.02 · 5 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Da Vinci Surgical System, OTEZLA, PREVNAR 20, REPATHA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error